Publication:
The potential for emerging microbiome-mediated therapeutics in asthma

dc.contributor.coauthorTurturice, Benjamin Arthur
dc.contributor.coauthorPerkins, David L.
dc.contributor.coauthorFinn, Patricia W.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorÖztürk, Ayşe Bilge
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:53:08Z
dc.date.issued2017
dc.description.abstractPurpose of Review In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics. Recent Findings Recent clinical and basic studies to date have identified several possible therapeutics that can target innate immunity and the microbiota in asthma. Some of these drugs have shown beneficial effects in the treatment of certain asthma phenotypes and for protection against asthma during early life. Summary Current clinical evidence does not support the use of these therapies for effective treatment of asthma. The integration of the data regarding microbiota with technologic advances, such as next generation sequencing and omics offers promise. Combining comprehensive bioinformatics, new molecules and approaches may shape future asthma treatment.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue9
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipTurkish Thoracic Society Fellowship Programme Dr. Öztürk would like to thank the Turkish Thoracic Society Fellowship Programme for supporting her work at the UIC Department of Medicine Finn-Perkins Laboratory.
dc.description.volume17
dc.identifier.doi10.1007/s11882-017-0730-1
dc.identifier.eissn1534-6315
dc.identifier.issn1529-7322
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85027863993
dc.identifier.urihttps://doi.org/10.1007/s11882-017-0730-1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/14966
dc.identifier.wos410900800005
dc.keywordsAsthma
dc.keywordsInnate immunity
dc.keywordsInterleukin-33
dc.keywordsMicrobiota
dc.keywordsThymic stromal lymphopoietin
dc.keywordsToll-like receptors
dc.language.isoeng
dc.publisherCurrent Medicine Group
dc.relation.ispartofCurrent Allergy and Asthma Reports
dc.subjectAllergy
dc.subjectImmunology
dc.titleThe potential for emerging microbiome-mediated therapeutics in asthma
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorÖztürk, Ayşe Bilge
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files